Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7,230,838
-
Total 13F shares
-
2,367,676
-
Share change
-
-48,017
-
Total reported value
-
$31,511,176
-
Price per share
-
$13.31
-
Number of holders
-
40
-
Value change
-
-$410,540
-
Number of buys
-
19
-
Number of sells
-
13
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q4 2024
As of 31 Dec 2024,
Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,367,676 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Redmile Group, LLC, CITADEL ADVISORS LLC, BANK OF AMERICA CORP /DE/, VANGUARD GROUP INC, Vestal Point Capital, LP, ACADIAN ASSET MANAGEMENT LLC, TANG CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, and BlackRock, Inc..
This page lists
41
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.